A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma
Status:
Unknown status
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether ribociclib are effective and safe in the
treatment of progressive well/dedifferentiated liposarcoma (WDL/DDL).